Bank of America Corp DE Purchases 731,962 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Bank of America Corp DE grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 1,165.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 794,761 shares of the company’s stock after purchasing an additional 731,962 shares during the quarter. Bank of America Corp DE owned approximately 1.51% of Janux Therapeutics worth $42,552,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of JANX. Russell Investments Group Ltd. increased its position in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Janux Therapeutics during the 4th quarter valued at about $139,000. Meeder Asset Management Inc. bought a new position in shares of Janux Therapeutics during the 4th quarter valued at about $159,000. Tower Research Capital LLC TRC increased its position in shares of Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock valued at $205,000 after purchasing an additional 3,436 shares during the last quarter. Finally, Chicago Capital LLC bought a new position in shares of Janux Therapeutics during the 4th quarter valued at about $230,000. 75.39% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Wedbush restated an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Scotiabank reduced their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $95.25.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $22.62 on Thursday. Janux Therapeutics, Inc. has a fifty-two week low of $22.48 and a fifty-two week high of $71.71. The stock has a 50 day simple moving average of $28.89 and a two-hundred day simple moving average of $41.16. The stock has a market cap of $1.34 billion, a P/E ratio of -19.33 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $30.00, for a total value of $100,020.00. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at $2,464,170. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the stock in a transaction dated Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 10,001 shares of company stock worth $313,964. 8.10% of the stock is currently owned by company insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.